Shares of QTTB stock opened at $3.70 on Thursday. Q32 Bio has a 12-month low of $3.67 and a 12-month high of $53.79. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a ...

Get Our Latest Research Report on QTTB Q32 Bio Price Performance Q32 Bio stock opened at $3.70 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio ...

There are 156 funds or institutions reporting positions in Q32 Bio. This is an increase of 81 owner(s) or 108.00% in the last quarter. Average portfolio weight of all funds dedicated to QTTB is 0. ...

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the announcement of “disappointing” topline results from ...

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares. The firm notes Q32 Bio reported negative AD but positive AA results ...

On Wednesday, Wells Fargo (NYSE:WFC) adjusted its stance on Q32 Bio Inc. (NASDAQ:QTTB), downgrading the stock from Overweight to Equal Weight and significantly reducing the price target to $16.00 from ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Q32 Bio ( (QTTB)) has shared an update. Q32 Bio announced encouraging results from its SIGNAL-AA Phase 2a trial ...

In the SIGNAL-AA trial, bempikibart showed a 16% mean SALT score reduction vs. 2% for placebo. Q32 Bio plans a Phase 2a expansion for bempikibart in alopecia areata, enrolling ~20 more patients ...

On Wednesday, Piper Sandler adjusted its price target for Q32 Bio Inc. (NASDAQ: QTTB) shares, a clinical-stage biopharmaceutical company, from $85.00 to $20.00 while maintaining an Overweight ...